Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2008-07-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1158/1535-7163.MCT-08-0017PMID 18606717
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery

  2008cited by this paper
• Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway.

  2008cited by this paper
• The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations

  2007cited by this paper
• The Structure of a Human p110a/p85a Complex Elucidates the Effects of Oncogenic PI3Ka Mutations

  2007cited by this paper
• Chemically targeting the PI3K family.

  2007cited by this paper
• The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.

  2007cited by this paper
• AKT/PKB signaling: navigating downstream.

  2007cited by this paper
• Signalling through Class I PI3Ks in mammalian cells.

  2006cited by this paper
• mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s.

  2006cited by this paper
• Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability.

  2006cited by this paper
• A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.

  2006cited by this paper
• Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor.

  2006cited by this paper
• Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1.

  2006cited by this paper
• Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

  2006cited by this paper
• Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity.

  2006cited by this paper
• Cancer-specific mutations in PIK3CA are oncogenic in vivo

  2006cited by this paper
• The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

  2006cited by this paper
• Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner.

  2006cited by this paper
• mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.

  2006cited by this paper
• SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity.

  2006cited by this paper
• Ras, PI(3)K and mTOR signalling controls tumour cell growth

  2006cited by this paper
• Mutant PIK3CA promotes cell growth and invasion of human cancer cells.

  2005cited by this paper
• The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.

  2005cited by this paper
• Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.

  2005cited by this paper
• The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells

  2005cited by this paper
• Drug Insight: temozolomide as a treatment for malignant glioma—impact of a recent trial

  2005cited by this paper
• Recent advances in the protein kinase B signaling pathway.

  2005cited by this paper
• From worm to human: bioinformatics approaches to identify FOXO target genes.

  2005cited by this paper
• Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex

  2005cited by this paper
• Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

  2005cited by this paper
• Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence.

  2005cited by this paper
• DNA damage-induced activation of ATM and ATM-dependent signaling pathways.

  2004cited by this paper
• The in vivo role of PtdIns(3,4,5)P3 binding to PDK1 PH domain defined by knockin mutation

  2004cited by this paper
• High Frequency of Mutations of the PIK3CA Gene in Human Cancers

  2004cited by this paper
• Cancer genes and the pathways they control

  2004cited by this paper
• High-Throughput Screening with Quantitation of ATP Consumption: A Universal Non-Radioisotope, Homogeneous Assay for Protein Kinase

  2004cited by this paper
• In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase.

  2004influential reference
• Inactivation of the Tuberous Sclerosis Complex-1 and -2 Gene Products Occurs by Phosphoinositide 3-Kinase/Akt-dependent and -independent Phosphorylation of Tuberin*

  2003cited by this paper
• DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation

  2003cited by this paper
• Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty

  2003cited by this paper
• Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.

  2002cited by this paper
• Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling

  2002cited by this paper
• Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo.

  2002cited by this paper
• Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment.

  2001cited by this paper
• Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR

  2001cited by this paper
• Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice.

  2001cited by this paper
• Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells.

  2000cited by this paper
• Phosphatidylinositol 3-Kinase Signaling Controls Levels of Hypoxia-inducible Factor 11

  2000cited by this paper
• Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine.

  2000cited by this paper
• Signal transduction by the JNK group of MAP kinases.

  2000cited by this paper
• Structural insights into phosphoinositide 3-kinase catalysis and signalling

  1999cited by this paper
• Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase.

  1994cited by this paper
• A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002).

  1994cited by this paper

• Bladder cancer-induced CVD mortality: Role of CAPG protein.

  2026cites this paper
• Targeting ATR in Cancer therapy: A drug discovery perspective.

  2026cites this paper
• Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization

  2025cites this paper
• Research Progress on PI3K/AKT/mTOR Signaling Pathway and Multidrug Resistance in Breast Cancer

  2025cites this paper
• Identification of a Novel Peptide from Agaricus blazei Murrill and Its Immune-Enhancing Activity by Regulation of PI3K/AKT/mTOR Signaling Pathways in RAW 264.7 Cells

  2025cites this paper
• Recent advances of the mechanistic target of rapamycin (mTOR) inhibitors for drug discovery.

  2025cites this paper
• Chondrosarcoma: Multi-Targeting Therapeutic Effects of Doxorubicin, BEZ235, and the Small Molecule Aspartyl-Asparaginyl-β-hydroxylase Inhibitor SMI1182

  2025cites this paper
• Pericyte phenotype switching in cancer.

  2025cites this paper
• Heterogeneous Activation of Signaling Pathways and Therapeutic Vulnerabilities in KSHV‐Associated Primary Effusion Lymphoma Cell Lines

  2025cites this paper
• Multi-scale in-silico modelling to unveil structural requirements for DNA-PK inhibitors as radiosensitizers and MolSHAP based design of novel ligands

  2025cites this paper
• All-trans retinoic acid enhances anti-proliferative effect of dual PI3K and mTOR inhibitor NVP-BEZ235 in triple negative breast cancer

  2025cites this paper
• Targeting the PI3K/AKT/mTOR pathway in lung cancer: mechanisms and therapeutic targeting

  2025cites this paper
• Recent progress in developing ATR inhibitors as anticancer agents.

  2025cites this paper
• Carbohydrate kinase inhibition: a promising strategy in cancer treatment.

  2025cites this paper
• mTOR signaling networks: mechanistic insights and translational frontiers in disease therapeutics

  2025cites this paper
• The mTOR pathway in Gliomas: From molecular insights to targeted therapies.

  2025cites this paper
• Phosphatidylinositol kinases in GtoPdb v.2025.1

  2025cites this paper
• Carrier-Free Cisplatin–Dactolisib Nanoparticles for Enhanced Synergistic Antitumor Efficacy

  2025cites this paper
• Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma

  2025cites this paper
• The Landscape of Potential Targeted Treatments and Chemotherapy Efficacy Biomarkers for TNBC

  2025cites this paper
• Phosphatidylinositol-4,5-bisphosphate 3-kinase family in GtoPdb v.2025.1

  2025cites this paper
• Novel anticancer inhibitors targeting the PI3K/Akt/mTOR signaling route and apoptosis inducers: A study on the apoptosis mechanism via the intrinsic mitochondrial-mediated pathway.

  2025cites this paper
• Current Understanding of the Role of Autophagy in the Treatment of Myeloid Leukemia

  2024cites this paper
• Pericyte phenotype switching alleviates immunosuppression and sensitizes vascularized tumors to immunotherapy in preclinical models

  2024cites this paper
• Small Molecular Inhibitors That Target ATM for Drug Discovery: Current Research and Potential Prospective.

  2024cites this paper
• From lab to clinic: The discovery and optimization journey of PI3K inhibitors.

  2024cites this paper
• Establishment and Application of Novel Hypoxia-driven Dual-reporter Model to Investigate Hypoxic Impact on Radiation Sensitivity in Human Nasopharyngeal Carcinoma Xenografts

  2024cites this paper
• Autophagy Blockage Up-Regulates HLA-Class-I Molecule Expression in Lung Cancer and Enhances Anti-PD-L1 Immunotherapy Efficacy

  2024cites this paper
• Targeting a lineage-specific PI3Kɣ–Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule

  2024cites this paper
• Unveiling the Role of PIK3R1 in Cancer: A Comprehensive Review of Regulatory Signaling and Therapeutic Implications.

  2024cites this paper
• β-carboline derivative Z86 attenuates colorectal cancer cell proliferation and migration by directly targeting PI3K

  2024cites this paper
• Targeted Treatment against Cancer Stem Cells in Colorectal Cancer

  2024cites this paper
• A novel dual ATM/DNA-PK inhibitor, XRD-0394, potently radiosensitizes and potentiates PARP and topoisomerase I inhibitors.

  2024cites this paper
• Emerging Therapies for Glioblastoma

  2024cites this paper
• PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment

  2024cites this paper
• Altered lipid homeostasis and autophagy precipitate diffuse alveolar hemorrhage in murine lupus

  2024cites this paper
• Identification of 6-Anilino Imidazo[4,5-c]pyridin-2-ones as Selective DNA-Dependent Protein Kinase Inhibitors and Their Application as Radiosensitizers

  2024cites this paper
• Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects.

  2023cites this paper
• Dual targeting of melanoma translation by MNK/eIF4E and PI3K/mTOR inhibitors.

  2023cites this paper
• Molecular simulations required to target novel and potent inhibitors of cancer invasion

  2023cites this paper
• The Marine Natural Compound Dragmacidin D Selectively Induces Apoptosis in Triple-Negative Breast Cancer Spheroids

  2023cites this paper
• Anti-cancer effect of palmatine through inhibition of the PI3K/AKT pathway in canine mammary gland tumor CMT-U27 cells

  2023cites this paper
• Mutant PIK3CA as a negative predictive biomarker for treatment with a highly selective PIM1 inhibitor in human colon cancer

  2023cites this paper
• Discovery of N-(2-chloro-5-(3-(pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl)pyridin-3-yl)-4-fluorobenzenesulfonamide (FD274) as a highly potent PI3K/mTOR dual inhibitor for the treatment of acute myeloid leukemia.

  2023cites this paper
• MNK, mTOR or eIF4E-selecting the best anti-tumor target for blocking translation initiation.

  2023cites this paper
• Phosphatidylinositol kinases in GtoPdb v.2023.1

  2023cites this paper
• The regulation of PTEN: Novel insights into functions as cancer biomarkers and therapeutic targets

  2023cites this paper
• PI3K/AKT/mTOR Signaling Pathway in HPV-Driven Head and Neck Carcinogenesis: Therapeutic Implications

  2023cites this paper
• Novel Cellular Functions of ATR for Therapeutic Targeting: Embryogenesis to Tumorigenesis

  2023cites this paper
• The mTOR Signaling Pathway and mTOR Inhibitors in Cancer: Next-generation Inhibitors and Approaches.

  2023cites this paper
• The myocardium utilizes a platelet-derived growth factor receptor alpha (Pdgfra)–phosphoinositide 3-kinase (PI3K) signaling cascade to steer toward the midline during zebrafish heart tube formation

  2023cites this paper
• Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario

  2023cites this paper
• Molecular Insight into Drug Resistance Mechanism Conferred by Aberrant PIK3CD Splice Variant in African American Prostate Cancer

  2023cites this paper
• Cu-Catalyzed Decarboxylative Annulation of N-Phenylglycines with Maleimides: Synthesis of 1H-Pyrrolo[3,4-c]quinoline-1,3(2H)-diones.

  2023cites this paper
• High-Throughput/High Content Imaging Screen Identifies Novel Small Molecule Inhibitors and Immunoproteasomes as Therapeutic Targets for Chordoma

  2023cites this paper
• Phosphatidylinositol-4,5-bisphosphate 3-kinase family in GtoPdb v.2023.1

  2023cites this paper
• CHKB-AS1 enhances proliferation and resistance to NVP-BEZ235 of renal cancer cells via regulating the phosphorylation of MAP4 and PI3K/AKT/mTOR signaling

  2023cites this paper
• Targeted Glioblastoma Therapy by Integrating Brain-Targeting Peptides and Corn-derived Cancer Cell-Penetrating Proteins into Nanoparticles to Cross Blood-Brain Tumor Barriers

  2023cites this paper
• Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.

  2022cites this paper
• Development and Evolution of DNA-Dependent Protein Kinase Inhibitors toward Cancer Therapy

  2022cites this paper
• Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.

  2022cites this paper
• Targeting mTOR in the context of diet and whole-body metabolism.

  2022cites this paper
• Kanserde Hedefe Yönelik Tedavi: PI3K/Akt/mTOR İnhibitörleri

  2022cites this paper
• Enhancing autophagy in Alzheimer's disease through drug repositioning.

  2022cites this paper
• RNA interference screens discover proteases as synthetic lethal partners of PI3K inhibition in breast cancer cells

  2022cites this paper
• Emerging Roles for Mammalian Target of Rapamycin (mTOR) Complexes in Bladder Cancer Progression and Therapy

  2022cites this paper
• Differential kinase activity across prostate tumor compartments defines sensitivity to target inhibition.

  2022cites this paper
• Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment

  2022cites this paper
• Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma

  2022cites this paper
• Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents.

  2022cites this paper
• Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions.

  2022cites this paper
• Discovery of 2-Methyl-2-(4-(2-methyl-8-(1H-pyrrolo[2,3-b]pyridin-6-yl)-1H-naphtho[1,2-d]imidazol-1-yl)phenyl)propanenitrile as a Novel PI3K/mTOR Inhibitor with Enhanced Antitumor Efficacy In Vitro and In Vivo.

  2022cites this paper
• Norkurarinone and isoxanthohumol inhibit high glucose and hypoxia-induced angiogenesis via improving oxidative stress and regulating autophagy in human retinal microvascular endothelial cells.

  2022cites this paper
• Mild replication stress causes premature centriole disengagement via a sub-critical Plk1 activity under the control of ATR-Chk1

  2022cites this paper
• Modern treatment approaches to adult acute T-lymphoblastic and myeloid/T-lymphoblastic leukemia: from current standards to precision medicine

  2022cites this paper
• Anti-cancerous medications and PTEN treatment modalities for the control of endometrial malignancy

  2022cites this paper
• Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy

  2022cites this paper
• NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition

  2022cites this paper
• Genetic characterization and drug sensitivity study of newly derived HGBL double/triple-hit lymphoma cell lines

  2022cites this paper
• Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015-2021).

  2022cites this paper
• Dual PI3K/mTOR Inhibitor NVP-BEZ235 Leads to a Synergistic Enhancement of Cisplatin and Radiation in Both HPV-Negative and -Positive HNSCC Cell Lines

  2022cites this paper
• Jagged-1 is induced by mTOR inhibitors in renal cancer cells through an Akt/ALK5/Smad4-dependent mechanism

  2022cites this paper
• Advances in Immunosuppressive Agents Based on Signal Pathway

  2022cites this paper
• NSCLC Cells Resistance to PI3K/mTOR Inhibitors Is Mediated by Delta-6 Fatty Acid Desaturase (FADS2)

  2022cites this paper
• Ribosomal Protein S6: A Potential Therapeutic Target against Cancer?

  2021cites this paper
• Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma

  2021cites this paper
• Ponatinib, Lestaurtinib, and mTOR/PI3K Inhibitors Are Promising Repurposing Candidates against Entamoeba histolytica

  2021cites this paper
• mTOR Signaling Pathways

  2021cites this paper
• Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer

  2021cites this paper
• Overcoming chemotherapy resistance in endometrial cancer

  2021cites this paper
• Metal-free site-selective C–H cyanoalkylation of 8-aminoquinoline and aniline-derived amides with azobisisobutyronitrile

  2021cites this paper
• Molecular mechanisms involved in DNA repair in human cancers: An overview of PI3k/Akt signaling and PIKKs crosstalk

  2021cites this paper
• Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy

  2021cites this paper
• Selective therapeutic benefit of X-rays and inhibitors of EGFR, PI3K/mTOR, and Bcl-2 in breast, lung, and cervical cancer cells.

  2021cites this paper
• BET protein inhibition evidently enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma

  2021cites this paper
• Investigational new drugs against glioblastoma

  2021cites this paper
• A novel PI3K inhibitor XH30 suppresses orthotopic glioblastoma and brain metastasis in mice models

  2021cites this paper
• Recent Applications of Pd-Catalyzed Suzuki-Miyaura and Buchwald-Hartwig Couplings in Pharmaceutical Process Chemistry.

  2021cites this paper
• Sensors and Inhibitors for the Detection of Ataxia Telangiectasia Mutated (ATM) Protein Kinase.

  2021cites this paper
• Anticancer potential of novel α,β-unsaturated γ-lactam derivatives targeting the PI3K/AKT signaling pathway.

  2021cites this paper